MiMedx Group (MDXG) Competitors $9.10 +0.02 (+0.22%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MDXG vs. PRCT, AXNX, NVCR, NVST, NARI, IRTC, LIVN, ENOV, WRBY, and CNMDShould you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. MiMedx Group vs. PROCEPT BioRobotics Axonics NovoCure Envista Inari Medical iRhythm Technologies LivaNova Enovis Warby Parker CONMED PROCEPT BioRobotics (NASDAQ:PRCT) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Do analysts rate PRCT or MDXG? PROCEPT BioRobotics presently has a consensus price target of $97.86, suggesting a potential upside of 20.56%. MiMedx Group has a consensus price target of $12.00, suggesting a potential upside of 31.87%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than PROCEPT BioRobotics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PRCT or MDXG? In the previous week, PROCEPT BioRobotics had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for PROCEPT BioRobotics and 2 mentions for MiMedx Group. PROCEPT BioRobotics' average media sentiment score of 1.35 beat MiMedx Group's score of 0.20 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community believe in PRCT or MDXG? MiMedx Group received 7 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. Likewise, 81.82% of users gave MiMedx Group an outperform vote while only 67.86% of users gave PROCEPT BioRobotics an outperform vote. CompanyUnderperformOutperformPROCEPT BioRoboticsOutperform Votes3867.86% Underperform Votes1832.14% MiMedx GroupOutperform Votes4581.82% Underperform Votes1018.18% Which has more volatility and risk, PRCT or MDXG? PROCEPT BioRobotics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PRCT or MDXG? 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 1.3% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, PRCT or MDXG? MiMedx Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPROCEPT BioRobotics$199.84M21.20-$105.90M-$1.95-41.63MiMedx Group$342.80M3.90$58.23M$0.5516.55 Is PRCT or MDXG more profitable? MiMedx Group has a net margin of 23.86% compared to PROCEPT BioRobotics' net margin of -50.07%. MiMedx Group's return on equity of 26.21% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets PROCEPT BioRobotics-50.07% -38.57% -26.06% MiMedx Group 23.86%26.21%18.15% SummaryMiMedx Group beats PROCEPT BioRobotics on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get MiMedx Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDXG vs. The Competition Export to ExcelMetricMiMedx GroupSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$4.34B$5.12B$9.07BDividend YieldN/A41.46%4.91%4.22%P/E Ratio16.5525.3791.3417.19Price / Sales3.9045.681,116.59116.80Price / Cash50.3143.4542.6437.86Price / Book9.297.364.794.78Net Income$58.23M$13.64M$120.07M$225.60M7 Day Performance-0.66%-2.80%-1.89%-1.24%1 Month Performance-1.30%0.56%11.45%3.36%1 Year Performance1.34%41.87%30.61%16.58% MiMedx Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDXGMiMedx Group2.8171 of 5 stars$9.10+0.2%$12.00+31.9%+1.7%$1.34B$342.80M16.55895High Trading VolumePRCTPROCEPT BioRobotics2.7844 of 5 stars$89.54+0.3%$97.86+9.3%+102.9%$4.67B$136.19M0.00626Positive NewsAXNXAxonics1.4327 of 5 stars$70.98+0.8%$71.00+0.0%+20.9%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.7422 of 5 stars$32.84-1.7%$32.67-0.5%+138.4%$3.55B$577.74M-23.861,453NVSTEnvista3.9012 of 5 stars$19.59+0.6%$20.65+5.4%-21.1%$3.37B$2.50B-2.5112,800NARIInari Medical3.3152 of 5 stars$55.39-0.4%$58.89+6.3%-11.9%$3.24B$574.50M-41.181,300Analyst ForecastInsider TradeIRTCiRhythm Technologies3.2186 of 5 stars$89.50+3.6%$107.82+20.5%-14.3%$2.80B$492.68M-17.782,000Analyst ForecastGap DownLIVNLivaNova3.5889 of 5 stars$50.15-2.6%$69.17+37.9%-4.4%$2.72B$1.24B122.622,900Analyst UpgradePositive NewsENOVEnovis3.0125 of 5 stars$46.56+0.9%$67.00+43.9%-21.5%$2.60B$2.00B-21.396,550Positive NewsWRBYWarby Parker1.5745 of 5 stars$24.24+2.6%$20.73-14.5%+99.1%$2.46B$669.77M-87.523,491Insider TradeCNMDCONMED4.6156 of 5 stars$71.69-1.2%$79.80+11.3%-36.7%$2.21B$1.29B17.234,000Positive News Related Companies and Tools Related Companies PROCEPT BioRobotics Alternatives Axonics Alternatives NovoCure Alternatives Envista Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives LivaNova Alternatives Enovis Alternatives Warby Parker Alternatives CONMED Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MDXG) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiMedx Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDXG Stock Alerts